Loading
Latest filing published 30 Jul 2025 for Lexaria Bioscience Corp., €591.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vanessa Carle appears in our data through filings on Lexaria Bioscience Corp. shares, published by SEC (Form 4). In total, 3 filings cover trades dated from 14 May 2024 to 29 July 2025.
Both buying and selling appear: 1 purchase worth €591, against 1 sale worth €9,486. The net balance comes to €8,896 on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 1 option exercise. 2025 to date brings 1 purchase and no sales.
The record was last updated on 30 July 2025 with an open-market purchase (€591) in Lexaria Bioscience Corp. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations